Peripheral cannabinoid 1 receptor blockade mitigates adipose tissue inflammation via NLRP3 inflammasome in mouse models of obesity. Issue 9 (5th June 2018)

• Record Type: Journal Article
• Authors: Han, Ji H.; Shin, Hanho; Rho, Jun G.; Kim, Jung‐Eun; Son, Dong H.; Yoon, Juhwan; Lee, Yong J.; Park, Jung‐Hyuck; Song, Byung J.; Choi, Chang‐Sik; Yoon, Seul G.; Kim, Il Y.; Lee, Eun K.; Seong, Je K.; Kim, Ki W.; Kim, Wook
• Is Part Of: Diabetes, obesity & metabolism. Volume 20:Issue 9(2018)
• Page Start: 2179
• Page End: 2189
• Publication Date: 2018-06-05
• Subjects: adipose tissue inflammation -- insulin resistance -- obesity -- peripheral cannabinoid 1 receptor; Diabetes -- Periodicals; Obesity -- Periodicals; Metabolism -- Disorders -- Periodicals; Clinical pharmacology -- Periodicals; 616.462
• DOI: 10.1111/dom.13350
• Languages: English
• ISSNs: 1462-8902

Abstract

Abstract : Aim: To analyze the metabolic parameters and adipose tissue inflammation via NLRP3 inflammasome following chronic treatment of mouse models of obesity with AJ5018 as the peripherally restricted cannabinoid 1 receptor (CB1R) antagonist. Materials and methods: The selectivity for CB1R over CB2R, brain/plasma concentration ratio, and centrally mediated neurobehavioural effects of AJ5018, were assessed. The long‐term effects of AJ5018 and rimonabant on the metabolic parameters and adipose tissue inflammation were analyzed in diet‐induced obese (DIO) mice and diabetic db/db mice. Results: AJ5018 had a higher degree of selectivity for CB1R over CB2R and markedly reduced brain penetrance, as reflected by the lower brain/plasma concentration ratio and the attenuated centrally mediated neurobehavioural effects, compared with its brain‐penetrant parent compound rimonabant. In DIO and db/db mice, AJ5018 exhibited comparable effects to rimonabant in improving metabolic abnormalities and suppressing macrophage infiltration into white adipose tissue, activation of the NLRP3 inflammasome, and production of proinflammatory cytokines. Conclusions: These results suggest that peripheral CB1R blockade improves obesity‐induced insulin resistance by suppressing adipose tissue inflammation via the NLRP3 inflammasome.